CNTB Connect Biopharma Holdings Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835268 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY382.0%
TTM net income YoY-37.9%
TTM EPS YoY-28.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,879.9%
Net margin-1,849.7%
FCF margin-1,504.2%
EBITDA margin-1,861.7%
Returns
ROE-201.5%
ROA-142.8%
ROIC (approx.)-834.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets56.6%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $736,000 | $2.77M | $169,000 | $0 | $16,000 | $48,000 | $0 | $698,000 |
| R&D expense | $12.79M | $16.27M | $15.03M | $11.28M | $11.11M | $8.77M | $6.63M | $6.24M |
| SG&A expense | $4.26M | $4.10M | $4.75M | $4.24M | $6.58M | $4.70M | $4.81M | $4.08M |
| Operating income | -$16.31M | -$17.60M | -$19.61M | -$15.53M | -$17.68M | -$13.42M | -$11.45M | -$9.62M |
| Pretax income | -$16.13M | -$17.22M | -$19.35M | -$15.08M | -$17.14M | -$12.84M | -$10.22M | -$8.80M |
| Income tax | $20,000 | $60,000 | $48,000 | $27,000 | $61,000 | $55,000 | $54,000 | $106,000 |
| Net income | -$16.15M | -$17.28M | -$19.40M | -$15.11M | -$17.20M | -$12.90M | -$10.27M | -$8.91M |
| EBITDA | -$16.15M | -$17.44M | -$19.44M | -$15.35M | -$17.50M | -$13.25M | -$11.27M | -$9.46M |
| EPS (basic) | -0.26 | -0.27 | -0.34 | — | -0.31 | -0.23 | -0.19 | — |
| EPS (diluted) | -0.26 | -0.27 | -0.34 | — | -0.31 | -0.23 | -0.19 | — |
| Weighted avg. shares (diluted) | 62.97M | 62.88M | 56.55M | — | 55.72M | 55.50M | 55.35M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16.50M | $27.02M | $46.03M | $38.34M | $37.84M | $40.63M | $47.71M | $78.23M |
| Short-term investments | $2.99M | $4.47M | $0 | $6.00M | $16.94M | $31.14M | $36.29M | $15.48M |
| Receivables | $788,000 | $2.94M | $0 | $13,000 | $17,000 | $0 | $8,000 | $789,000 |
| Current assets | $23.14M | $38.62M | $55.02M | $50.93M | $62.60M | $77.76M | $87.75M | $96.96M |
| PP&E, net | $3.48M | $3.60M | $3.70M | $3.81M | $3.94M | $4.05M | $3.91M | $4.05M |
| Intangibles | $40,000 | $42,000 | $43,000 | $45,000 | $47,000 | $48,000 | $50,000 | $53,000 |
| Total assets | $27.77M | $43.47M | $60.07M | $56.08M | $67.36M | $82.72M | $92.69M | $101.28M |
| Current liabilities | $15.49M | $16.30M | $17.05M | $13.61M | $11.43M | $10.74M | $8.56M | $8.46M |
| Total liabilities | $15.71M | $16.61M | $17.44M | $14.10M | $11.99M | $11.38M | $9.79M | $9.12M |
| Shareholders' equity | $12.05M | $26.86M | $42.62M | $41.98M | $55.37M | $71.34M | $82.90M | $92.17M |
| Shares outstanding | 62.99M | 62.97M | 62.71M | 56.44M | 55.79M | 55.58M | 55.35M | 55.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.05M | -$15.92M | -$16.00M | -$11.25M | -$17.41M | -$12.59M | -$9.96M | -$2.32M |
| Capital expenditure | $6,000 | $0 | $0 | $16,000 | $34,000 | $303,000 | $81,000 | $313,000 |
| Free cash flow | -$12.06M | -$15.92M | -$16.00M | -$11.27M | -$17.44M | -$12.89M | -$10.04M | -$2.63M |
| Investing cash flow | $1.49M | -$4.47M | $6.00M | $10.98M | $14.35M | $5.13M | -$20.64M | -$15.76M |
| Financing cash flow | $0 | $1.33M | $17.62M | $715,000 | $215,000 | $161,000 | $2,000 | $106,000 |
| Depreciation & amortization | $162,000 | $161,000 | $164,000 | $181,000 | $179,000 | $171,000 | $173,000 | $158,000 |
| Stock-based compensation | $1.26M | $1.26M | $1.20M | $917,000 | $916,000 | $951,000 | $942,000 | $1.40M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.